Galectin Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Galectin Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- GALT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001133416
Board of directors
-
Benjamin Carson Sr. · DirectorSince 2023
-
Elissa J. Schwartz · DirectorSince 2023
-
Gilbert F. Amelio · DirectorSince 2023
-
Gilbert S. Omenn · DirectorSince 2023
-
Harold H. Shlevin · DirectorSince 2023
-
Henry Brem · DirectorSince 2026
-
James C. Czirr · DirectorSince 2023
-
Joel Lewis · Director · President and CEOSince 2023
-
Kary Eldred · DirectorSince 2023
-
Kevin D. Freeman · DirectorSince 2023
-
Marc Rubin · DirectorSince 2023
-
Richard A. Zordani Jr. · DirectorSince 2023
-
Richard E. Uihlein · DirectorSince 2023
Chief executives
Joel Lewis
· President and CEO
Dates unknown
Board connections
3 of this board's directors also sit on 5 other boards.
- via Gilbert S. Omenn
- via Benjamin Carson Sr.
- via Marc Rubin
- via Benjamin Carson Sr.
- via Benjamin Carson Sr.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,557
- 4 purchases by 2 insiders
- Sold, last 12 months
- $6,069,797
- 67 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Richard E. Uihlein Director, 10% owner | Option exercise | +31,825,235 | $3.00 | $95,475,705 |
| Jul 31, 2026 | Richard E. Uihlein Director, 10% owner | Option exercise | +2,550,932 | $4.05 | $10,331,275 |
| Jul 14, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +16,250 | $3.04 | $49,400 |
| Jul 14, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −16,250 | $5.13 | $83,285 |
| Jun 29, 2026 | Harold H. Shlevin Director | Option exercise | +22,268 | $1.23 | $27,390 |
| Jun 29, 2026 | Harold H. Shlevin Director | Open-market sale | −22,268 | $5.04 | $112,231 |
| Jun 29, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +47,467 | $2.50 | $118,668 |
| Jun 29, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −47,467 | $5.04 | $239,234 |
| Jun 26, 2026 | Harold H. Shlevin Director | Option exercise | +7,732 | $1.23 | $9,510 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +2,037 | $2.20 | $4,481 |
| Jun 26, 2026 | Harold H. Shlevin Director | Open-market sale | −7,732 | $5.00 | $38,660 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −2,037 | $5.00 | $10,185 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +2,533 | $2.50 | $6,333 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −2,533 | $5.00 | $12,665 |
| Jun 23, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +7,557 | $1.23 | $9,295 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.